Search - tctmd.com

Displaying 741 - 760 of 988

Sort: Relevancy | Date

Presentation

Ticagrelor vs. Clopidogrel in Patients with ACS and a History of Stroke or TIA

Presenter: Stefan K. James

May 31, 2012

News Daily News

TRITON-TIMI 38 Analysis: In CABG Patients, Mortality Benefit with Prasugrel Despite Higher Bleeding Risk

L.A. McKeown

May 29, 2012

News Daily News

Análisis TRITON-TIMI 38: En Pacientes sometidos a CABG, se observa un Beneficio en la Mortalidad con el Prasgurel aunque también un Mayor Riesgo Hemorrágico

L.A. McKeown

May 29, 2012

News Daily News

Se Publica el GIFT: Confirmado el Papel del CYP2C19 en la Variabilidad de la Respuesta al Clopidogrel

L.A. McKeown

May 23, 2012

News Daily News

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

L.A. McKeown

May 23, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Daily News

Meta-analysis: Superior Efficacy with DES at No Cost to Safety

May 22, 2012

News Daily News

Meta Análisis: Superior Eficacia de los SLF sin poner en Peligro la Seguridad

May 22, 2012

Presentation

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

Presenter: Matthew J. Price

May 22, 2012

News Conference News EuroPCR 2012

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Caitlin E. Cox

May 18, 2012

News Conference News EuroPCR 2012

Statin Reloading Improves Clinical Outcomes in Stable PCI Patients

Jason Kahn

May 17, 2012

News Daily News

Una Prueba Temprana de Esfuerzo Físico tras una PCI Primaria resulta Simple, Segura y Económica

May 10, 2012

News Daily News

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

May 10, 2012

News Daily News

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 09, 2012

News Daily News

El Cambio en un Prospecto de la FDA No Disipa las Dudas sobre el Uso de PPI con Clopidogrel

Caitlin E. Cox

May 09, 2012

News Features

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 07, 2012

News Daily News

Una Dosis Alta de Recarga de Prasugrel es Mejor a la hora de Suprimir la Reactividad Plaquetaria que Antecede a una PCI

Jason Kahn

May 01, 2012

News Daily News

High Prasugrel Reloading Dose Best for Suppressing Platelet Reactivity Prior to PCI

Jason Kahn

May 01, 2012

News Daily News

Switching to Non-CYP3A4-Metabolized Statins May Reduce High Platelet Reactivity

April 25, 2012

News Daily News

Cambiar a Estatinas No Metabolizadas por CYP3A4 podría Reducir la Alta Reactividad Plaquetaria

April 25, 2012

Advertisement

Ticagrelor vs. Clopidogrel in Patients with ACS and a History of Stroke or TIA

TRITON-TIMI 38 Analysis: In CABG Patients, Mortality Benefit with Prasugrel Despite Higher Bleeding Risk

Análisis TRITON-TIMI 38: En Pacientes sometidos a CABG, se observa un Beneficio en la Mortalidad con el Prasgurel aunque también un Mayor Riesgo Hemorrágico

Se Publica el GIFT: Confirmado el Papel del CYP2C19 en la Variabilidad de la Respuesta al Clopidogrel

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Meta-analysis: Superior Efficacy with DES at No Cost to Safety

Meta Análisis: Superior Eficacia de los SLF sin poner en Peligro la Seguridad

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Statin Reloading Improves Clinical Outcomes in Stable PCI Patients

Una Prueba Temprana de Esfuerzo Físico tras una PCI Primaria resulta Simple, Segura y Económica

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

El Cambio en un Prospecto de la FDA No Disipa las Dudas sobre el Uso de PPI con Clopidogrel

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Una Dosis Alta de Recarga de Prasugrel es Mejor a la hora de Suprimir la Reactividad Plaquetaria que Antecede a una PCI

High Prasugrel Reloading Dose Best for Suppressing Platelet Reactivity Prior to PCI

Switching to Non-CYP3A4-Metabolized Statins May Reduce High Platelet Reactivity

Cambiar a Estatinas No Metabolizadas por CYP3A4 podría Reducir la Alta Reactividad Plaquetaria

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content